Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks, reflecting a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.
VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns. The agreement brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects.
The partnership positions VERAXA to potentially benefit more than others from AI’s growing impact on drug R&D. By leveraging AI to analyze complex biological data and identify drug targets, the company aims to improve clinical development decisions and increase the probability of success for its BiTAC platform. The collaboration is intended to strengthen development of VERAXA’s oncology pipeline through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).
As the pharmaceutical industry increasingly adopts machine learning to enhance research productivity, VERAXA’s focus on combining AI with its innovative antibody engineering could provide a competitive edge. The BiTAC technology, which uses a Boolean “AND-gate” logic to engage T-cells only when two specific antigens are present, aims to minimize off-target effects and improve safety profiles. AI-assisted target selection may help identify the most promising dual-target pairs that were previously overlooked due to safety concerns, potentially reviving abandoned drug candidates.
The broader context of this collaboration includes a wave of AI partnerships across the biotech sector, as companies seek to improve the efficiency of drug development. For VERAXA, the AI collaboration with Ardigen represents a strategic move to accelerate its pipeline and reduce the high attrition rates typical of oncology drug discovery. The partnership underscores the growing importance of computational approaches in identifying and validating therapeutic targets, particularly in complex fields like cancer immunotherapy.
